NEW YORK (GenomeWeb News) – Royalty payments received by BG Medicine from its development and commercialization partners may be reduced following the establishment of a payment rate for the firm's galectin-3 test by the US Centers for Medicare and Medicaid Services, the company said recently in i
BG medicine is hopeful that data from two studies published earlier this year will help shore up the scientific foundation for the company's new strategy of marketing its galectin-3 test to hospitals as a tool for reducing unplanned readmissions.
Bolstered by a recent $10 million financing round and a 19-country distribution pact, Irvine, Calif.-based biotech firm Aviir is pushing its MIRISK VP protein biomarker test into the increasingly crowded cardiac risk assessment market.
NEW YORK (GenomeWeb News) – Trovagene said this week that it will collaborate with researchers at the University of Texas MD Anderson Cancer Center on detecting transrenal BRAF mutations in the urine of patients with advanced or metastatic cancers.
NEW YORK (GenomeWeb News) – BG Medicine said after the close of the market Friday that it has received notice from the Listing Qualifications Department of the Nasdaq Stock Market that it is not in compliance with one of the requirements for continued listing.